Long-term real-world evidence for sustained clinical benefits of fingolimod following switch from natalizumab

Conclusions: In patients discontinuing natalizumab, fingolimod has a favorable benefit–risk profile over 48 months. These findings also suggest using a short washout following natalizumab discontinuation, consistent with guidelines and current clinical practice in Germany.
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research

Related Links:

Publication date: Available online 22 January 2020Source: Annals of Physical and Rehabilitation MedicineAuthor(s): Claire Hentzen, Nicolas Turmel, Camille Chesnel, Audrey Charlanes, Frédérique Le Breton, Samer Sheikh Ismaël, Gérard AmarencoAbstractBackground: Lower urinary tract symptoms, especially overactive bladder, are frequent and disabling in individuals with multiple sclerosis (IwMS). An association with gait disorders is common, which could aggravate continence difficulties and affect quality of life. The association between the need to void and walking has never been studied in this popul...
Source: Annals of Physical and Rehabilitation Medicine - Category: Rehabilitation Source Type: research
Publication date: Available online 22 January 2020Source: The Lancet NeurologyAuthor(s): Jeremy Chataway, Floriana De Angelis, Peter Connick, Richard A Parker, Domenico Plantone, Anisha Doshi, Nevin John, Jonathan Stutters, David MacManus, Ferran Prados Carrasco, Frederik Barkhof, Sebastien Ourselin, Marie Braisher, Moira Ross, Gina Cranswick, Sue H Pavitt, Gavin Giovannoni, Claudia Angela Gandini Wheeler-Kingshott, Clive Hawkins, Basil SharrackSummaryBackgroundNeurodegeneration is the pathological substrate that causes major disability in secondary progressive multiple sclerosis. A synthesis of preclinical and clinical re...
Source: The Lancet Neurology - Category: Neurology Source Type: research
Conclusions: In MS patients, polypharmacy is common and closely associated with health issues. There is a great need for research in this area, especially regarding longitudinal changes in drug utilization. Effective networks between physicians and pharmacists are needed to optimize medication management for patients and to achieve the best possible therapy results. PMID: 31965869 [PubMed - as supplied by publisher]
Source: Expert Opinion on Drug Safety - Category: Drugs & Pharmacology Tags: Expert Opin Drug Saf Source Type: research
DiscussionThe adapted MAM-36 showed adequate psychometric properties. However, indications of problematic targeting to PwMS with low disability emerged. For this reason, use of the scale appears to be more suitable among patients with moderate-to-severe disability.
Source: Neurological Sciences - Category: Neurology Source Type: research
Aerobic training has the potential to restore function, stimulate brain repair, and reduce inflammation in people with Multiple Sclerosis (MS). However, disability, fatigue, and heat sensitivity are major barr...
Source: BMC Neurology - Category: Neurology Authors: Tags: Research article Source Type: research
Conclusions: Treatment of highly active RRMS with cladribine tablets was less costly and more effective than treatment with fingolimod. Hence, it is a dominant strategy in the Portuguese setting. No conclusions can be drawn from the present study regarding other treatment options, in particular natalizumab and alemtuzumab. PMID: 31951777 [PubMed - as supplied by publisher]
Source: Journal of Medical Economics - Category: Health Management Tags: J Med Econ Source Type: research
ConclusionsDelayed treatment start in this POMS cohort was associated with shorter time to reach sustained EDSS 4 and confirmed EDSS worsening, and decreased chance of reaching confirmed EDSS improvement, and thus support early treatment start in POMS patients.
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research
Conclusions: In this matching-adjusted comparison of patients with RMS from three phase 3 trials, a significantly lower proportion of patients treated with SC peginterferon beta-1a 125 mcg every 2 weeks than with oral teriflunomide 14 mg once daily had 24-week CDW at 108 weeks. In addition, in both the overall population and newly diagnosed patient subgroups, ARR at 108 weeks was numerically lower with peginterferon beta-1a than with teriflunomide. The numerically lower ARR in newly diagnosed patients treated with peginterferon beta-1a compared with those treated with teriflunomide was sustained through up to 5 years of treatment.
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research
AbstractCrucial elements for achieving optimal long-term outcomes in multiple sclerosis (MS) are patient confidence and effective physician –patient communication. Patient-reported instruments may provide the means to fill the gap in currently available clinician-rated measures. The SymptoMScreen (SMSS) is a brief self-assessment tool for measuring symptom severity in 12 neurologic domains commonly affected by MS. We conducted a non-i nterventional study to assess the dimensional structure and item characteristics of the SMSS. A total of 218 patients with relapsing–remitting MS and mild disability (median Expan...
Source: Neurology and Therapy - Category: Neurology Source Type: research
ConclusionFindings could help further understand the alleviation of the detrimental impacts of CPZ using the OLs that would be capable of increasing the level of S100, MAG, and MBP.
Source: Journal of Chemical Neuroanatomy - Category: Neuroscience Source Type: research
More News: Disability | Germany Health | Gilenya | Multiple Sclerosis | Neurology | Study | Tysabri